|
EA028052B1
(ru)
|
2012-11-08 |
2017-10-31 |
Бристол-Майерс Сквибб Компани |
АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
|
|
CA2890983A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyridyl compounds useful as kinase modulators
|
|
PE20150944A1
(es)
|
2012-11-08 |
2015-06-20 |
Bristol Myers Squibb Co |
COMPUESTOS HETEROCICLICOS SUSTITUIDOS CON AMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE INTERLEUCINA 12(IL-12), INTERLEUCINA 23 (IL-23) Y/O INTERFERON ALFA (IFN(alfa))
|
|
AR094537A1
(es)
|
2013-11-07 |
2015-08-12 |
Bristol Myers Squibb Co |
COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
|
|
JP6458038B2
(ja)
|
2013-12-10 |
2019-01-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
|
|
UY35935A
(es)
|
2014-01-03 |
2015-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
WO2016022626A1
(en)
*
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
EP3313840B1
(en)
|
2015-06-24 |
2019-07-24 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
ES2822956T3
(es)
|
2015-06-24 |
2021-05-05 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituidos con heteroarilo
|
|
KR102641263B1
(ko)
|
2015-06-24 |
2024-02-26 |
브리스톨-마이어스 스큅 컴퍼니 |
헤테로아릴 치환된 아미노피리딘 화합물
|
|
CU24506B1
(es)
|
2015-11-26 |
2021-04-07 |
Novartis Ag |
Derivados de diamino piridina útiles paea tratar enfermedades susceptibles a la modulación de jak
|
|
JP7082130B2
(ja)
|
2016-10-14 |
2022-06-07 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
JP7046092B2
(ja)
*
|
2016-12-13 |
2022-04-01 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物
|
|
US10336752B2
(en)
|
2017-03-08 |
2019-07-02 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors, uses, and methods for production thereof
|
|
AU2018265130B2
(en)
|
2017-05-11 |
2022-03-24 |
Bristol-Myers Squibb Company |
Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
|
|
TWI776810B
(zh)
*
|
2017-05-12 |
2022-09-11 |
瑞士商諾華公司 |
新穎二胺基吡啶衍生物
|
|
WO2019023468A1
(en)
|
2017-07-28 |
2019-01-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
KR102702228B1
(ko)
*
|
2017-11-21 |
2024-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
술폰 피리딘 알킬 아미드-치환된 헤테로아릴 화합물
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3752142A4
(en)
|
2018-02-13 |
2021-09-08 |
Rutgers, The State University of New Jersey |
ANTIBACTERIAL AGENTS: SOLUBLE SALTS AND AQUEOUS FORMULATIONS OF PYRONINS
|
|
US11685723B2
(en)
|
2018-02-13 |
2023-06-27 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: O-alkyl-deuterated pyronins
|
|
US11572337B2
(en)
|
2018-03-06 |
2023-02-07 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: arylalkylcarboxamido phloroglucinols
|
|
UY38144A
(es)
|
2018-03-12 |
2019-10-31 |
Abbvie Inc |
Inhibidores de la señalización mediada por tirosina cinasa
|
|
EP3768667B1
(en)
*
|
2018-03-22 |
2023-04-12 |
Bristol-Myers Squibb Company |
Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
AU2019360941B2
(en)
|
2018-10-15 |
2025-02-27 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
EA202191142A1
(ru)
*
|
2018-10-30 |
2021-07-20 |
Бристол-Маерс Сквибб Компани |
Амидзамещенные гетероциклические соединения
|
|
JP7530360B2
(ja)
|
2018-11-30 |
2024-08-07 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
KR20250167680A
(ko)
|
2018-11-30 |
2025-12-01 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
CN113348021B
(zh)
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
KR20210119426A
(ko)
*
|
2019-01-28 |
2021-10-05 |
장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 |
피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
|
|
ES2960521T3
(es)
|
2019-07-18 |
2024-03-05 |
Bristol Myers Squibb Co |
Compuestos de pirazolo[3,4-D]pirrolo[1,2-B]piridazinilo útiles como inhibidores de IRAK4
|
|
EP3999508B1
(en)
|
2019-07-18 |
2023-08-30 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
WO2021016289A1
(en)
|
2019-07-23 |
2021-01-28 |
Bristol-Myers Squibb Company |
Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
|
|
WO2021026181A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
Bicyclic heterocyclic compounds useful as irak4 inhibitors
|
|
JP2022547719A
(ja)
|
2019-09-13 |
2022-11-15 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニストおよびその使用
|
|
US12391702B2
(en)
|
2020-02-03 |
2025-08-19 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
|
|
CN115335380B
(zh)
|
2020-02-03 |
2024-08-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的三环杂芳基化合物
|
|
US20220330549A1
(en)
*
|
2020-03-11 |
2022-10-20 |
Northwest A&F University |
Use of n-benzylbenzamide-based compound as herbicide
|
|
KR20230004612A
(ko)
*
|
2020-04-14 |
2023-01-06 |
고사머 바이오 서비시즈 인코포레이티드 |
염증성 질병의 치료를 위한 치환된 피리딘
|
|
KR20230004771A
(ko)
|
2020-04-28 |
2023-01-06 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
|
|
JP7537002B2
(ja)
*
|
2020-08-07 |
2024-08-20 |
南京薬石科技股▲フン▼有限公司 |
Ｃｄｋ９阻害剤およびその使用
|
|
CN114181257B
(zh)
*
|
2020-09-14 |
2025-02-14 |
四川科伦博泰生物医药股份有限公司 |
吡啶类化合物，包含其的药物组合物，其制备方法及其用途
|
|
JP2023546996A
(ja)
|
2020-10-23 |
2023-11-08 |
ニンバス クロソー， インコーポレイテッド |
Ｃｔｐｓ１阻害剤およびその使用
|
|
US20240076285A1
(en)
*
|
2020-12-16 |
2024-03-07 |
Shankar Venkatraman |
Compounds and compositions for treating conditions associated with sting activity
|
|
JP2024503300A
(ja)
|
2020-12-30 |
2024-01-25 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
WO2022175745A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
KR20230159420A
(ko)
*
|
2021-02-19 |
2023-11-21 |
수도 바이오사이언시즈 리미티드 |
Tyk2 억제제 및 이의 용도
|
|
EP4294807A1
(en)
*
|
2021-02-19 |
2023-12-27 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
AU2022222470A1
(en)
|
2021-02-19 |
2023-09-21 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12071442B2
(en)
|
2021-03-29 |
2024-08-27 |
Nimbus Saturn, Inc. |
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
|
|
CA3214952A1
(en)
|
2021-04-09 |
2022-10-13 |
Silvana Marcel LEIT DE MORADEI |
Cbl-b modulators and uses thereof
|
|
KR20240111312A
(ko)
|
2021-10-25 |
2024-07-16 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Tyk2 분해제 및 이의 용도
|
|
AU2022378630A1
(en)
|
2021-10-29 |
2024-05-09 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
CN118401516A
(zh)
*
|
2021-12-16 |
2024-07-26 |
凌科药业(杭州)有限公司 |
Tyk2抑制剂及其组合物和方法
|
|
WO2023108536A1
(en)
*
|
2021-12-16 |
2023-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
CN116693449A
(zh)
*
|
2022-03-04 |
2023-09-05 |
上海致根医药科技有限公司 |
用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
|
|
CN119585250A
(zh)
*
|
2022-04-19 |
2025-03-07 |
蓝图药品公司 |
Kit抑制剂
|
|
EP4532485A1
(en)
*
|
2022-05-27 |
2025-04-09 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
KR20250057800A
(ko)
|
2022-08-02 |
2025-04-29 |
리미널 바이오사이언시스 리미티드 |
헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
IL318576A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
Pyridoxine-substituted GPR84 antagonists and their uses
|
|
WO2024249855A1
(en)
*
|
2023-06-02 |
2024-12-05 |
Idrx, Inc. |
Combination therapy comprising kit inhibitors for use in the treatment of cancer
|
|
TW202529769A
(zh)
|
2023-09-21 |
2025-08-01 |
日商武田藥品工業股份有限公司 |
Ｔｙｋ２抑制劑及其用途
|